Renin-Angiotensin System Dysregulation as Severe COVID-19 Factor: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Cardiac & Cardiovascular Systems
Contributor:
Sarzani Riccardo

Since the first months of the coronavirus disease 2019 (COVID-19) pandemic, several specific physiologic traits, such as male sex and older age, or health conditions, such as overweight/obesity, arterial hypertension, metabolic syndrome, and type 2 diabetes mellitus, have been found to be highly prevalent and associated with increased risk of adverse outcomes in hospitalized patients. All these cardiovascular morbidities are widespread in the population and often coexist, thus identifying a common patient phenotype, characterized by a hyper-activation of the “classic” renin-angiotensin system (RAS) and mediated by the binding of angiotensin II (Ang II) to the type 1-receptor. At the same time, the RAS imbalance was proved to be crucial in the genesis of lung injury after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, where angiotensin-converting-enzyme-2 (ACE2) is not only the receptor for SARS-CoV-2, but its down-regulation through internalization and shedding, caused by the virus binding, leads to a further dysregulation of RAS by reducing angiotensin 1-7 (Ang 1-7) production. 

  • COVID-19
  • SARS-CoV-2
  • cardiovascular disease
  • renin-angiotensin system

1. Introduction

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in December 2019 in Wuhan, China [1]. Since then, COVID-19 has exponentially spread all around the world, making the World Health Organization (WHO) declaring it a pandemic on March 11, 2020. Until now, there have been millions of deaths worldwide. Since the first months of the pandemic, several specific physiologic traits, such as male sex and older age, or health conditions, such as overweight/obesity, arterial hypertension, metabolic syndrome, and type 2 diabetes mellitus, have been found to be highly prevalent and associated with increased risk of adverse outcomes in hospitalized COVID-19 patients [2]. The first report on hospitalized COVID-19 patients in Wuhan found that hypertension (31.2%), diabetes mellitus (10.1%), cardiovascular disease (14.5%), and malignancy (17.2%) were the most common related health conditions [3]. In March 2020, the American College of Cardiology (ACC) issued a clinical bulletin confirming that patients suffering from hypertension, diabetes, and cardiovascular disease had higher case fatality rates than the average population. In a large case series of sequentially hospitalized COVID-19 patients in the New York City area between March 2020 and April 2020, the most common comorbidities were hypertension (56.6%), obesity (41.7%), and diabetes (33.8%) [4]. Furthermore, meta-analytic data confirmed significant positive correlations between COVID-19 severity and hypertension, diabetes, and coronary heart disease [5]. Case-control studies have reported that obesity, together with diabetes and hypertension, were the strongest predictors for COVID-19, being associated not only with illness severity but also with higher risk of acquiring the infection [6].

2. Disequilibrium between ACE and ACE2 Activity as a Potential Causal Mechanism for Severe COVID-19

The RAS plays a fundamental role in the regulation of fluid volume and blood pressure, but it also exerts a large spectrum of effects on several tissues, especially those that are microvasculature-rich, such as the lungs. Renin, a protease produced by renal juxtaglomerular cells in its active form, cleaves angiotensinogen, released mainly by the liver, to form Ang I. A pathophysiological mechanism underlying the cardio-metabolic conditions associated with a greater risk of morbidity and mortality in COVID-19 is the imbalance between ACE and its homologous ACE2, with a decreased activity of the latter and impairment of its protective effects. Similarly to ACE, ACE2 is a ubiquitous enzyme, particularly expressed in the lungs but also present on the enterocytes of the small intestine and on the endothelial cells of several organs and systems, such as the brain, cardiovascular system, and kidney [7][8]. ACE and ACE2 are key enzymes in the metabolism of Ang I: ACE, expressed widespread by endothelial cells, catalyzes the conversion of Ang I to the octapeptide Ang II [9], which exerts its effects via Ang II type 1 and type 2 receptors (AT1R and AT2R, respectively). In particular, binding of Ang II to AT1R is the one most commonly expressed in normal adult tissues, stimulating vasoconstriction, sodium reabsorption, and blood pressure increase, promoting vascular damage, inflammation, and fibrosis [10]. On the opposite side, ACE2 is a type I transmembrane metallocarboxypeptidase that cleaves Ang I into a nonapeptide [Ang (1-9)] that binds AT2R and Ang II into a heptapeptide [Ang (1-7)] that binds its specific receptor, initially identified as an “oncogene” (Mas receptor, MasR) [11]. The two main effects of ACE2 are thereby the degradation of Ang II, the principal effector of the “classic” RAS arm through AT1R, and the production of Ang (1-7), which exerts opposite effects by inducing vasodilatation as well as anti-inflammatory and anti-fibrotic pathways through binding to the MasR [12]. ACE2 also interacts with another sub-branch of RAS based on Ang peptides in which the aminoterminal aspartate is replaced by alanine (Alatensins), leading to the production of Ala-Ang (1-7) (Alamandine) that has been found to bind Mas-related G protein-coupled receptor D (MrgD) and may also protect against lung injury and fibrosis, improving vascular/endothelial dysfunction [8]. The ACE2/Ang (1-7)/MasR axis has been found to attenuate inflammation and fibrosis in experimental models to prevent heart failure and coronary heart disease [13], as well as lung injury [14][15]. Therefore, ACE2 plays a pivotal role in the modulation of the two main arms of RAS: the ACE/Ang II/AT1R axis (“classic RAS”) and the ACE2/Ang (1-7)/MasR axis (“anti-RAS”). Indeed, ACE2 antagonizes “classic RAS”, playing an essential counter-regulatory role in the activation of the “anti-RAS” [16]. As SARS-CoV-2 uses ACE2 as a primary receptor to gain entry into human cells, causing its functional down-regulation through internalization and shedding [17][18], coronavirus infection leads to a RAS dysregulation, enhancing the ACE/Ang II/AT1R pathway up to vascular “toxicity”, causing microvascular damage and dysregulated vascular permeability. This results in capillary leakage of protein and fibrin-rich edema filling alveolar spaces, also promoting oxidative stress and inflammation, leading to acute respiratory distress syndrome (ARDS) [19]. Moreover, the ACE/Ang II/AT1R axis is likely to promote the production of inflammatory cytokines, accelerate apoptosis in alveolar epithelial cells and promote extracellular matrix synthesis, resulting in lung fibrosis, a hallmark of tissue injury in SARS-CoV-2-related pneumonia [20]. On the other hand, Ang (1-7) has been found to mitigate inflammation, counteract lung fibrosis, and improve oxygenation in acute lung injury, acting as a protective factor against ARDS [14]. The main cardio-metabolic conditions associated with a worse outcome in COVID-19 are intertwined via RAS imbalance at baseline.

3. Overweight, Obesity, Visceral Adiposity and Metabolic Syndrome

Obesity and overweight with visceral adiposity promote increased circulating levels of Ang I, leading to an overproduction of Ang II and hyper-activation of “classic RAS” [21][22]. Adipocytes produce and release all the components of “classic RAS”, including angiotensinogen, ACE, and Ang II, with the only exception of renin, even if they express the renin receptor [23][24]. Thus, in the context of the aforementioned SARS-CoV-2-induced ACE2 downregulation, it is likely that the increased levels of both Ang I and Ang II coming from visceral adipose tissue lead to an ACE/Ang II/AT1R “storm” affecting the pulmonary microcirculation in obese COVID-19 patients [25]. In addition, obese subjects show high circulating levels of microRNAs involved in the downregulation of ACE2, resulting in further basal dysfunction of ACE2 compared to healthy subjects [26]. Adipose tissue is also involved in cytokine and adipokine secretion, contributing to a pro-inflammatory environment. Indeed, leptin, one of the main adipokines secreted by adipocytes, has been found to be related to increased Ang II levels and decreased ACE2 expression [27]. Moreover, the deficiency of the natriuretic peptide (NP) system, found in obese subjects, mainly due to an increased expression of the clearance NP receptor C [28], could further contribute to the RAS imbalance in this population. In fact, both A-type (ANP) and B-type (BNP) NPs counteract the typical features of the ACE/Ang II/AT1R axis hyper-activation (endothelial dysfunction and increased permeability, pro-inflammatory, pro-hypertrophic, and pro-fibrotic activity), while experimental studies found that ANP can prevent the reduction in ACE2 mediated by Ang II and, conversely, Ang (1-7) can increase ANP release [22][29]. These interactions with RAS, together with their natriuretic and cardio-protective effects against acute cardiac dysfunction that may develop during SARS-CoV-2 infection, give NPs an important role in COVID-19, especially if obesity and heart failure are present [30].
Overall, obesity and overweight can increase the risk for severe COVID-19 through several mechanistic, biochemical, and immunological pathways; among them, the dysregulation of RAS is likely to play a key role in increasing both disease severity and mortality (Figure 1).
Jcm 10 05883 g001 550
Figure 1. Overweight/obesity, renin-angiotensin-system, and lung injury caused by SARS-CoV-2. ACE, angiotensin-converting-enzyme; Ang, angiotensin; AT1R, angiotensin II type 1 receptor; Mas R, Mas receptor.

4. Type 2 Diabetes Mellitus

New-onset hyperglycemia or acute decompensated diabetes mellitus have been frequently observed in COVID-19 patients [31][32]. Moreover, susceptibility to other overlapped secondary infections, together with the use of glucocorticoid therapy, can further precipitate acute hyperglycemia [33] with increased plasma osmolality, osmotic polyuria and dehydration, endothelial dysfunction, thrombophilia, and amplified pro-inflammatory cytokine secretion, all key factors in SARS-CoV-2-related multi-organ dysfunction. In addition, binding of SARS-CoV-2 to ACE2 in pancreatic cells can damage islets and reduce insulin release, leading to acute hyperglycemia and transient diabetes [34]. The evidence that diabetes mellitus causes a pro-inflammatory environment has been corroborated by serum levels of inflammation biomarkers, such as interleukin-6 (IL-6), C-reactive protein (CRP), and ferritin, and D-dimer that are markedly higher in COVID-19 patients with diabetes mellitus compared to controls without diabetes [35]. Generally, diabetes mellitus is associated with weakened immune response and enhanced susceptibility to infections, due to inherent neutrophil dysfunction, reduced T-cell responses, and disordered humoral immunity [36]. As other cardio-metabolic comorbidities, type 2 diabetes mellitus bears the fingerprint of RAS imbalance: indeed, chronic activation of “classic RAS” is typical in diabetes and insulin-resistance, despite high sodium intake and high blood pressure, and contributes to microvascular and macrovascular complications and is clearly involved in diabetic kidney disease [37]. Furthermore, chronic hyperglycemia also reduces the ACE2 expression, with a loss of its anti-inflammatory effects and protection of endothelial function, because of a decreased counter-regulation of Ang II [38][39]. 

In the context of ACE/Ang II/AT1R axis hyper-activation, the insulin receptor also uses mitogen-activated protein (MAP) kinase as a downstream mediator of its action [23], mediating growth-factor-like effects, such as vascular smooth muscle growth and cardiac hypertrophy [40]. Even AT1R can activate MAP kinase in its post-receptor cascade, so it can be postulated that these two receptors synergize to exacerbate and perpetuate inflammation, fibrosis, and tissue injury. These findings are in line with the hypothesis that RAS dysregulation could be the backbone in the pathogenesis of severe COVID-19 in patients with diabetes mellitus. This vulnerability may play a synergistic role with the underpinning inflammatory milieu and immune defects associated with diabetes, providing SARS-CoV-2 a pathway for causing prolonged lung injury.

5. Arterial Hypertension

Worldwide epidemiologic data provided evidence that hypertension is a pivotal comorbidity related to COVID-19 disease severity.  In addition to the hypertensive condition, anti-hypertensive therapy is also likely to affect the course of COVID-19. A large meta-analysis enrolling 101,949 COVID-19 patients found a significant association between treatment with RAS inhibitors and mortality reduction among patients with hypertension [41].

The mechanisms by which hypertension leads to increased risk of worse outcome in COVID-19 are likely to be many. Hypertension is a major cardiovascular risk factor that promotes arteriosclerosis of large and small arteries and accelerates atherosclerosis, leading to cardiovascular disease and death. Left ventricular hypertrophy and myocardial fibrosis, with increased filling pressures and impaired coronary reserve, are key features that contribute to atrial fibrillation, myocardial ischemia, and heart failure with preserved ejection fraction [42]. Certainly, RAS hyper-activation or, at least, “inappropriately normal” renin activity and aldosterone levels are typical of overweight/obese hypertensive patients [21]. In these patients, normal or increased Ang II production results in a stimulation of the ACE/Ang II/AT1R pathway, leading to small arteries constriction, hypertrophy, fibrosis, and tissue injury [43]. It also leads to the activation of NADPH oxidases, with subsequent generation of reactive oxygen species, protein oxidation, and dysregulated cell signaling [44]. Moreover, animal models support a hypothetical link between hypertension and reduced ACE2 expression, corroborated by data showing lower expression of ACE2 mRNA and ACE2 protein expression in the kidneys of hypertensive rats [45].

6. Dyslipidemia

Another risk factor often associated with overweight/obesity and MetS is dyslipidemia. Although its influence may vary, according to age and the presence of other comorbidities, meta-analyses found that dyslipidemia was associated with higher mortality and disease severity [46][47]. Atherogenic dyslipidemia was more frequent in patients with critical COVID-19 and was significantly associated with intubation and death. High triglycerides levels were associated with high levels of inflammatory biomarkers and poor COVID-19 outcome during hospitalization [48].

7. Male Sex

From the early phases of the pandemic, male sex has been found to be associated to a more severe course of COVID-19 and greater need for intensive care, compared with female sex [49]. Studies found how men had a 59% increased risk for severe outcomes compared to women [50]. Observational studies reported how the vast majority (82%) of patients that needed intensive care were males [51] and how the main determinants of ICU admission were male sex and obesity [52].
Several factors can explain this sex difference. Although the greatest evidence on RAS and sex comes from preclinical studies, both types of sex hormones, estrogens and androgens, likely affect the expression and activity of several RAS components, especially regarding the “classic RAS” pathway, while limited data are available on the interactions with the counter-regulatory RAS components [53]. Estradiol is likely to cause a protective shift in ACE/ACE2 ratio, by both increasing ACE2 and inhibiting ACE expression [54]. Estrogenic activity has been found to inhibit the hemodynamic effects of Ang II and promote the action of ACE2/Ang (1-7) axis in animal models [55]. Estrogen has also been found to decrease tissue AT1R expression and aldosterone production, while testosterone conversely increases ACE activity and tissue AT1R expression [53]. Furthermore, the gene for ACE2 is located in the X chromosome, which could make it susceptible to escaping X-inactivation in women [56]. In an animal model of obesity-associated hypertension, the increase in blood pressure after high-fat diet is attenuated in females compared to males, and this different behavior appears to be mediated by ACE2 activity [57]. In humans, men tend to have higher levels of aldosterone than females, regardless of other confounders, facilitated, at least in part, by higher levels of endogenous Ang II [58].

8. Older Age

Several factors and age-related modifications are responsible for the increased risk of severe COVID-19 and death in older patients: the large spectrum of multiple cardio-metabolic morbidities, leading to a much higher cardiovascular risk, as well as immune-senescence, endothelial dysfunction, limited organ reserve (especially diminished cardiorespiratory function), and other psychosocial and nutritional factors [59]. In this large variety of factors, age-related decline in ACE2 expression, as observed in the lungs of rats [60], may play a non-negligible role. In older people, especially those with cardiovascular comorbidities, reduced ACE2 levels and increased Ang II signaling arrange a pro-inflammatory background. When these subjects are infected with SARS-CoV-2, that leads to a further reduction in ACE2 cell surface expression, there is a consequent overwhelmed amplification of the ACE/Ang II/AT1R pathway that perpetrates microvascular damage and inflammatory effects leading to severe lung injury [61]. It must be recalled that aging has a major role in cardiovascular disease by substantially “giving time” to multiple risk factors, even “borderline” in severity, to produce vascular damage through decades of inappropriate control [62]. When infections strike these older patients, the clinical scenario may often complicate with acute cardiovascular events, leading to more severe clinical course and worse outcome.

This entry is adapted from the peer-reviewed paper 10.3390/jcm10245883

References

  1. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020, 395, 565–574.
  2. Barison, A.; Aimo, A.; Castiglione, V.; Arzilli, C.; Lupón, J.; Codina, P.; Santiago-Vacas, E.; Cediel, G.; Emdin, M.; Bayes-Genis, A. Cardiovascular disease and COVID-19: Les liaisons dangereuses. Eur. J. Prev. Cardiol. 2020, 27, 1017–1025.
  3. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020, 323, 1061–1069.
  4. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; Barnaby, D.P.; Becker, L.B.; Chelico, J.D.; Cohen, S.L.; et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020, 323, 2052–2059.
  5. Meng, M.; Zhao, Q.; Kumar, R.; Bai, C.; Deng, Y.; Wan, B. Impact of cardiovascular and metabolic diseases on the severity of COVID-19: A systematic review and meta-analysis. Aging 2020, 12, 23409–23421.
  6. Hernández-Garduño, E. Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study. Obes. Res. Clin. Pract. 2020, 14, 375–379.
  7. Wiener, R.S.; Cao, Y.X.; Hinds, A.; Ramirez, M.I.; Williams, M.C. Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung. J. Cell. Biochem. 2007, 101, 1278–1291.
  8. Santos, R.A.S.; Oudit, G.Y.; Verano-Braga, T.; Canta, G.; Steckelings, U.M.; Bader, M. The renin-angiotensin system: Going beyond the classical paradigms. Am. J. Physiol. Heart Circ. Physiol. 2019, 316, H958–H970.
  9. Voors, A.A.; Pinto, Y.M.; Buikema, H.; Urata, H.; Oosterga, M.; Rooks, G.; Grandjean, J.G.; Ganten, D.; van Gilst, W. Dual pathway for angiotensin II formation in human internal mammary arteries. Br. J. Pharmacol. 1998, 125, 1028–1032.
  10. Ferrario, C.M.; Trask, A.J.; Jessup, J.A. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular function. Am. J. Physiol. Circ. Physiol. 2005, 289, H2281–H2290.
  11. Santos, R.A.S.; Simoes e Silva, A.C.; Maric, C.; Silva, D.M.R.; Machado, R.P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S.V.B.; Lopes, M.T.; Bader, M.; et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. USA 2003, 100, 8258–8263.
  12. Sanchis-Gomar, F.; Lavie, C.J.; Perez-Quilis, C.; Henry, B.M.; Lippi, G. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Mayo Clin. Proc. 2020, 95, 1222–1230.
  13. Arendse, L.B.; Danser, A.H.J.; Poglitsch, M.; Touyz, R.M.; Burnett, J.C., Jr.; Llorens-Cortes, C.; Ehlers, M.R.; Sturrock, E.D. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure. Pharmacol. Rev. 2019, 71, 539–570.
  14. Zambelli, V.; Bellani, G.; Borsa, R.; Pozzi, F.; Grassi, A.; Scanziani, M.; Castiglioni, V.; Masson, S.; Decio, A.; Laffey, J.G.; et al. Angiotensin-(1-7) improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental Acute Respiratory Distress Syndrome. Intensiv. Care Med. Exp. 2015, 3, 44.
  15. Imai, Y.; Kuba, K.; Rao, S.; Huan, Y.; Guo, F.; Guan, B.; Yang, P.; Sarao, R.; Wada, T.; Leong-Poi, H.; et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005, 436, 112–116.
  16. Paz Ocaranza, M.; Riquelme, J.A.; García, L.; Jalil, J.E.; Chiong, M.; Santos, R.A.S.; Lavandero, S. Counter-regulatory renin–angiotensin system in cardiovascular disease. Nat. Rev. Cardiol. 2020, 17, 116–129.
  17. Samavati, L.; Uhal, B.D. ACE2, Much More Than Just a Receptor for SARS-COV-2. Front. Cell. Infect. Microbiol. 2020, 10, 317.
  18. Glowacka, I.; Bertram, S.; Herzog, P.; Pfefferle, S.; Steffen, I.; Muench, M.O.; Simmons, G.; Hofmann, H.; Kuri, T.; Weber, F.; et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J. Virol. 2010, 84, 1198–1205.
  19. Sarzani, R.; Giulietti, F.; Di Pentima, C.; Giordano, P.; Spannella, F. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2020, 319, L325–L336.
  20. Uhal, B.D.; Li, X.; Piasecki, C.C.; Molina-Molina, M. Angiotensin signalling in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2012, 44, 465–468.
  21. Sarzani, R.; Salvi, F.; Dessì-Fulgheri, P.; Rappelli, A. Renin–angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: An integrated view in humans. J. Hypertens. 2008, 26, 831–843.
  22. Sarzani, R.; Spannella, F.; Giulietti, F.; Balietti, P.; Cocci, G.; Bordicchia, M. Cardiac Natriuretic Peptides, Hypertension and Cardiovascular Risk. High Blood Press. Cardiovasc. Prev. 2017, 24, 115–126.
  23. Zhou, M.-S.; Schulman, I.; Zeng, Q. Link between the renin–angiotensin system and insulin resistance: Implications for cardiovascular disease. Vasc. Med. 2012, 17, 330–341.
  24. Achard, V.; Boullu-Ciocca, S.; Desbriere, R.; Nguyen, G.; Grino, M. Renin receptor expression in human adipose tissue. Am. J. Physiol. Integr. Comp. Physiol. 2007, 292, R274–R282.
  25. de Leeuw, A.J.M.; Luttikhuis, M.A.M.O.; Wellen, A.C.; Müller, C.; Calkhoven, C.F. Obesity and its impact on COVID-19. J. Mol. Med. 2021, 99, 899–915.
  26. Papannarao, J.B.; Schwenke, D.O.; Manning, P.; Katare, R. Upregulated miR-200c is associated with downregulation of the functional receptor for severe acute respiratory syndrome coronavirus 2 ACE2 in individuals with obesity. Int. J. Obes. 2021, 1–4.
  27. Ibrahim, H.S.; Froemming, G.; Omar, E.; Singh, H.J. ACE2 activation by xanthenone prevents leptin-induced increases in blood pressure and proteinuria during pregnancy in Sprague-Dawley rats. Reprod. Toxicol. 2014, 49, 155–161.
  28. Sarzani, P.; Dessì-Fulgheri, P.; Paci, V.M.; Espinosa, E.; Rappelli, A. Expression of natriuretic peptide receptors in human adipose and other tissues. J. Endocrinol. Investig. 1996, 19, 581–585.
  29. Shah, A.; Gul, R.; Yuan, K.; Gao, S.; Oh, Y.-B.; Kim, U.-H.; Kim, S.H. Angiotensin-(1–7) stimulates high atrial pacing-induced ANP secretion via Mas/PI3-kinase/Akt axis and Na+/H+ exchanger. Am. J. Physiol. Circ. Physiol. 2010, 298, H1365–H1374.
  30. Rubattu, S.; Gallo, G.; Volpe, M. A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era. Front. Physiol. 2021, 12, 643721.
  31. Montefusco, L.; Ben Nasr, M.; D’Addio, F.; Loretelli, C.; Rossi, A.; Pastore, I.; Daniele, G.; Abdelsalam, A.; Maestroni, A.; Dell’Acqua, M.; et al. Acute and long-term disruption of glycometabolic control after SARS-Cov-2 infection. Nat. Metab. 2021, 3, 774–785.
  32. Rubino, F.; Amiel, S.A.; Zimmet, P.; Alberti, G.; Bornstein, S.; Eckel, R.H.; Mingrone, G.; Boehm, B.; Cooper, M.E.; Chai, Z.; et al. New-Onset Diabetes in COVID-19. N. Engl. J. Med. 2020, 383, 789–790.
  33. Sarzani, R.; Spannella, F.; Giulietti, F.; Di Pentima, C.; Giordano, P.; Giacometti, A. Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: A narrative review of the evidence. Intern. Emerg. Med. 2021, 1–10.
  34. Yang, J.-K.; Lin, S.-S.; Ji, X.-J.; Guo, L.-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010, 47, 193–199.
  35. Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C.; Qin, R.; Wang, H.; Shen, Y.; Du, K.; et al. Diabetes is a risk factor for the progression and prognosis of COVID -19. Diabetes/Metabolism Res. Rev. 2020, 36, e3319.
  36. Katulanda, P.; Dissanayake, H.A.; Ranathunga, I.; Ratnasamy, V.; Wijewickrama, P.S.A.; Yogendranathan, N.; Gamage, K.K.K.; De Silva, N.L.; Sumanatilleke, M.; Somasundaram, N.P.; et al. Prevention and management of COVID-19 among patients with diabetes: An appraisal of the literature. Diabetologia 2020, 63, 1440–1452.
  37. Patel, V.; Parajuli, N.; Oudit, G.Y. Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. Clin. Sci. 2014, 126, 471–482.
  38. Bornstein, S.R.; Dalan, R.; Hopkins, D.; Mingrone, G.; Boehm, B.O. Endocrine and metabolic link to coronavirus infection. Nat. Rev. Endocrinol. 2020, 16, 297–298.
  39. Santos, A.; Magro, D.O.; Evangelista-Poderoso, R.; Saad, M.J.A. Diabetes, obesity, and insulin resistance in COVID-19: Molecular interrelationship and therapeutic implications. Diabetol. Metab. Syndr. 2021, 13, 1–14.
  40. Hsueh, W.A.; Quiñones, M.J. Role of endothelial dysfunction in insulin resistance. Am. J. Cardiol. 2003, 92, 10J–17J.
  41. Baral, R.; Tsampasian, V.; Debski, M.; Moran, B.; Garg, P.; Clark, A.; Vassiliou, V.S. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19. JAMA Netw. Open 2021, 4, e213594.
  42. Sarzani, R.; Bordicchia, M.; Spannella, F.; Dessì-Fulgheri, P.; Fedecostante, M. Hypertensive heart disease and obesity: A complex interaction between hemodynamic and not hemodynamic factors. High Blood Press. Cardiovasc. Prev. 2014, 21, 81–87.
  43. Silva-Aguiar, R.P.; Peruchetti, D.B.; Rocco, P.R.M.; Schmaier, A.H.; e Silva, P.M.R.; Martins, M.A.; Carvalho, V.F.; Pinheiro, A.A.S.; Caruso-Neves, C. Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients. Am. J. Physiol. Lung Cell. Mol. Physiol. 2020, 319, L596–L602.
  44. Wingler, K.; Wünsch, S.; Kreutz, R.; Rothermund, L.; Paul, M.; Schmidt, H.H. Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic. Biol. Med. 2001, 31, 1456–1464.
  45. Crackower, M.A.; Sarao, R.; Oudit, G.Y.; Yagil, C.; Kozieradzki, I.; Scanga, S.E.; Oliveira-dos-Santos, A.J.; da Costa, J.; Zhang, L.; Pei, Y.; et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417, 822–828.
  46. Liu, Y.; Pan, Y.; Yin, Y.; Chen, W.; Li, X. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): A meta-analysis. Virol. J. 2021, 18, 157.
  47. Atmosudigdo, I.S.; Pranata, R.; Lim, M.A.; Henrina, J.; Yonas, E.; Vania, R.; Radi, B. Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression. J. Clin. Exp. Hepatol. 2021, 14, 1179551421990675.
  48. Bellia, A.; Andreadi, A.; Giudice, L.; De Taddeo, S.; Maiorino, A.; D’Ippolito, I.; Giorgino, F.M.; Ruotolo, V.; Romano, M.; Magrini, A.; et al. Atherogenic Dyslipidemia on Admission Is Associated with Poorer Outcome in People With and Without Diabetes Hospitalized for COVID-19. Diabetes Care 2021, 44, 2149–2157.
  49. Mo, P.; Xing, Y.; Xiao, Y.; Deng, L.; Zhao, Q.; Wang, H.; Xiong, Y.; Cheng, Z.; Gao, S.; Liang, K.; et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin. Infect. Dis. 2021, 73, e4208–e4213.
  50. Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020, 584, 430–436.
  51. Grasselli, G.; Zangrillo, A.; Zanella, A.; Antonelli, M.; Cabrini, L.; Castelli, A.; Cereda, D.; Coluccello, A.; Foti, G.; Fumagalli, R.; et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020, 323, 1574–1581.
  52. Iaccarino, G.; Grassi, G.; Borghi, C.; Carugo, S.; Fallo, F.; Ferri, C.; Giannattasio, C.; Grassi, D.; Letizia, C.; Mancusi, C.; et al. Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. PLoS ONE 2020, 15, e0237297.
  53. White, M.C.; Fleeman, R.; Arnold, A.C. Sex differences in the metabolic effects of the renin-angiotensin system. Biol. Sex Differ. 2019, 10, 31.
  54. Bukowska, A.; Spiller, L.; Wolke, C.; Lendeckel, U.; Weinert, S.; Hoffmann, J.; Bornfleth, P.; Kutschka, I.; Gardemann, A.; Isermann, B.; et al. Protective regulation of the ACE2/ACE gene expression by estrogen in human atrial tissue from elderly men. Exp. Biol. Med. 2017, 242, 1412–1423.
  55. Komukai, K.; Mochizuki, S.; Yoshimura, M. Gender and the renin-angiotensin-aldosterone system. Fundam. Clin. Pharmacol. 2010, 24, 687–698.
  56. Culebras, E.; Hernández, F. ACE2 is on the X chromosome: Could this explain COVID-19 gender differences? Eur. Heart J. 2020, 41, 3095.
  57. Gupte, M.; Thatcher, S.E.; Boustany-Kari, C.M.; Shoemaker, R.; Yiannikouris, F.; Zhang, X.; Karounos, M.; Cassis, L.A. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 1392–1399.
  58. Toering, T.J.; Gant, C.M.; Visser, F.W.; van der Graaf, A.M.; Laverman, G.D.; Danser, A.H.J.; Faas, M.M.; Navis, G.; Lely, A.T. Sex differences in renin-angiotensin-aldosterone system affect extracellular volume in healthy subjects. Am. J. Physiol. Renal Physiol. 2018, 314, F873–F878.
  59. Polidori, M.C.; Sies, H.; Ferrucci, L.; Benzing, T. COVID-19 mortality as a fingerprint of biological age. Ageing Res. Rev. 2021, 67, 101308.
  60. Xie, X.; Chen, J.; Wang, X.; Zhang, F.; Liu, Y. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006, 78, 2166–2171.
  61. AlGhatrif, M.; Cingolani, O.; Lakatta, E.G. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights from Cardiovascular Aging Science. JAMA Cardiol. 2020, 5, 747–748.
  62. Spannella, F.; Di Pentima, C.; Giulietti, F.; Buscarini, S.; Ristori, L.; Giordano, P.; Sarzani, R. Prevalence of Subclinical Carotid Atherosclerosis and Role of Cardiovascular Risk Factors in Older Adults: Atherosclerosis and Aging are Not Synonyms. High blood Press. Cardiovasc. Prev. Off. J. Ital. Soc. Hypertens. 2020, 27, 231–238.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback